

ClinicalTrials.gov Registration Data Elements for Interventional Studies (DRAFT)

* required by ClinicalTrials.gov
 FDAAA required to comply with PL 110-85, Section 801
 (FDAAA) may be required to comply with PL 110-85, Section 801

ClinicalTrials.gov Data Element	
1. Descriptive Information	
A	Brief Title* ^{FDAAA}
B	Brief Summary* ^{FDAAA}
C	Primary Purpose ^{FDAAA}
D	(Interventional) Study Design* ^(FDAAA)
	Intervention Model ^(FDAAA)
	Number of Arms ^(FDAAA)
	Masking ^(FDAAA)
	Allocation ^(FDAAA)
E	Study Phase* ^{FDAAA}
F	Study Type* ^{FDAAA}
G	Conditions or Focus of Study* ^{FDAAA}
H1	Intervention Type* ^{FDAAA}
H2	Intervention Name* ^{FDAAA}
	Intervention Description ^(FDAAA)
	Arms/Groups* ^(FDAAA)
	Arm Label or Number* ^(FDAAA)
	Arm Type* ^(FDAAA)
	Arm Description ^(FDAAA)
I	Study Start Date ^{FDAAA}
J	Primary Completion Date ^{FDAAA}
K	Enrollment (Target Number of Subjects) ^{FDAAA}
L	Primary and Secondary Outcome Measures ^{FDAAA}
	Outcome Measure ^{FDAAA}
	Outcome Time Frame ^(FDAAA)
M	Safety Issue? (Yes/No) ^(FDAAA)
2. Recruitment Information	
A	Eligibility Criteria* ^{FDAAA}
B	Gender* ^{FDAAA}
C	Age Limits* ^{FDAAA}
D	Accepts Healthy Volunteers? ^{FDAAA}
E	Overall Recruitment Status* ^{FDAAA}
F	Recruitment Status (Facility)* ^{FDAAA}
G1	Has Expanded Access? ^{FDAAA}
G2	Expanded Access Status ^{FDAAA}
3. Location and Contact Information	
A	Sponsor* ^{FDAAA}
B	Responsible Party ^{FDAAA}
	Name/Official Title ^{FDAAA}
	Organization ^{FDAAA}
	Contact Information ^{FDAAA}

* required by ClinicalTrials.gov

FDAAA required to comply with PL 110-85, Section 801

(FDAAA) may be required to comply with PL 110-85, Section 801

ClinicalTrials.gov Data Element (continued)	
C1	Facility* (FDAAA)
	Facility Name
	City* (FDAAA)
	State/Province* (FDAAA)
	Postal Code
	Country* (FDAAA)
C2	Facility Contact* (FDAAA) - or Central Contact
	First Name
	Middle Initial
	Last Name* (FDAAA)
	Degree
	Phone* (FDAAA) - or Email
	Ext.
	Email* (FDAAA) - or Phone
C3	Central Contact* (FDAAA) - or Facility Contact
	First Name
	Middle Initial
	Last Name* (FDAAA)
	Degree
	Phone* (FDAAA) - or Email
	Ext.
	Email* (FDAAA) - or Phone
4. Administrative Data	
A	Organization's Unique Protocol ID* FDAAA
B	Secondary IDs ^{FDAAA}
C1	IND/IDE Information
	IND/IDE Protocol?* (FDAAA)
	IND/IDE Grantor* (FDAAA)
	IND/IDE Number* (FDAAA)
	IND/IDE Serial Number ^(FDAAA)
C2	Record Verification Date* ^{FDAAA}
5. Other Necessary Information	
A	Applicable Clinical Trial
	FDA Regulated Intervention? ^(FDAAA)
	Section 801 Clinical Trial? ^(FDAAA)
	Delayed Posting? ^(FDAAA)
B	FDA Product Status - not yet implemented
C	Human Subjects Review - not required for IND/IDE or Federally funded studies
	Board Approval*
	Board Approval Status*
	Board Approval Number*
	Board Name*
	Board Affiliation*
	Board Contact* - at least phone or email
D	Oversight Authorities* - "US FDA" if yes to IND/IDE Protocol?
E	[NCT Number] - Assigned by ClinicalTrials.gov
F	[First Received Date] - Assigned by ClinicalTrials.gov